Perrigo Company plc (PRGO) Stock

Understand Perrigo Company plc: how it makes money

Perrigo makes store-brand OTC health products (pain relief, cold medicine, vitamins, digestive aids) sold to mass retailers and consumers. The mix is anchored in a large Self Care franchise with smaller Specialty Care and Infant Formula lines, all competing on price in a private-label space.

The model earns a thin margin on high-volume store-brand OTC manufacturing, so profitability depends almost entirely on factory throughput and volume, with no brand premium to cushion a demand decline.

Business quality (Weak): Weak. A -38% operating margin, -7% revenue trend, and -16% ROE signal a business under severe financial stress, likely weighed down by impairments or restructuring charges that overwhelm the modest product-level profit.

Bull case

• Gross margin holds at 34%: Despite the top-line decline, the 34% gross margin (10-Q) shows the store-brand OTC base still generates adequate unit economics per dollar of product sold. The core product mix is not structurally broken, and the margin is consistent with a manufacturing and distribution model.
• Self Care franchise anchors the mix: Self Care represents $540M, or 54% of revenue (10-Q), spanning essential categories like pain, upper respiratory, and digestive health. This broad, recurring consumer demand base is less vulnerable to a single-category disruption than a narrower portfolio would be.

Bear case

• Operating losses erase all gross profit: The -38% operating margin (10-Q) means the company is losing roughly 38 cents on every dollar of sales at the operating level. This implies substantial impairments, restructuring charges, or cost overruns that go far beyond the product-level economics and suggest the cost base is not aligned with revenue levels.
• Top line is in contraction mode: Quarterly revenue of $1.0B is down 7% year over year (10-Q), indicating store-brand OTC demand is softening. In a low-margin, volume-driven business, a 7% revenue drop is difficult to offset with cost savings because fixed manufacturing and distribution costs do not shrink proportionally.

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Alnylam Pharmaceuticals, Inc. (ALNY)
• BioMarin Pharmaceutical Inc. (BMRN)
• United Therapeutics Corporation (UTHR)
• Sarepta Therapeutics, Inc. (SRPT)
• PTC Therapeutics, Inc. (PTCT)
• Phibro Animal Health Corporation (PAHC)
• Vertex Pharmaceuticals Incorporated (VRTX)
• Regeneron Pharmaceuticals, Inc. (REGN)